Pfizer’s second Janus kinases (JAK) inhibitor ‘Cibinqo (abrocitinib) has landed and may be prescribed at general hospitals in Korea.

According to industry sources, Pfizer Korea’s new JAK1 inhibitor drug (abrocitinib) has passed the drug committee (DC) reviews of the ‘Big 5 tertiary hospitals’ of Korea including the Seoul National University Hospital, Seoul Asan Medical Center, Seoul St. Mary’s Hospital, Asan Medical Center, and Sinchon Severance Hospital, as well as 24 medical institutions including Gangnam Severance Hospital, Korea University Guro Hospital, and Seoul National University Bundang Hospital.

The company applied for its reimbursement listing in April, and as the agenda